Axsome Therapeutics (AXSM) Hisse Özeti
Bir biyofarmasötik şirketi olan Axsome Therapeutics, Inc. merkezi sinir sistemi (MSS) bozukluklarının yönetimi için yeni tedaviler geliştirmekte ve Amerika Birleşik Devletleri'nde sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 6/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden AXSM için herhangi bir risk tespit edilmedi.
AXSM Community Fair Values
Create NarrativeSee what 77 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Axsome Therapeutics, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$213.67 |
| 52 Haftanın En Yüksek Seviyesi | US$260.19 |
| 52 Haftanın En Düşük Seviyesi | US$109.40 |
| Beta | 0.73 |
| 1 Aylık Değişim | -7.10% |
| 3 Aylık Değişim | -6.04% |
| 1 Yıllık Değişim | 95.64% |
| 3 Yıllık Değişim | 201.88% |
| 5 Yıllık Değişim | 891.05% |
| Halka arzdan bu yana değişim | 2,344.74% |
Son Haberler & Güncellemeler
Analiz Makalesi • Aug 13
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
The second-quarter results for Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) were released last week, making it a good time...Seeking Alpha • Aug 11
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition
Summary Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but rising SG&A costs mostly offset commercial gains. Auvelity drove most revenues, benefiting from new Alzheimer's agitation indication and expanded sales force, yet profitability remains elusive. Management reiterates ambitious ~$8bn peak sales target for Auvelity, but current revenue trajectory and market dynamics cast doubt on achievability. I downgrade AXSM stock to Sell, citing persistent losses, questionable commercial scalability, and a market cap not justified by near-term revenue or profit outlook. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Aug 05
AXSM: Dementia Agitation Approval Will Drive Future Commercial Upside
Axsome Therapeutics' analyst fair value estimate has shifted from $148 to $242, as analysts factor in the recent Auvelity approval in dementia related agitation, higher projected revenue growth, and a richer future P/E assumption, partly offset by lower modeled profit margins and a slightly higher discount rate. Analyst Commentary Recent Street research on Axsome Therapeutics highlights a generally constructive stance on the stock, with a focus on the commercial opportunity for Auvelity and the contribution from other approved products.Recent updates
Analiz Makalesi • Aug 13
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
The second-quarter results for Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) were released last week, making it a good time...Seeking Alpha • Aug 11
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition
Summary Axsome Therapeutics, Inc. reported Q2 2026 net product revenue growth of 46% year-on-year, but rising SG&A costs mostly offset commercial gains. Auvelity drove most revenues, benefiting from new Alzheimer's agitation indication and expanded sales force, yet profitability remains elusive. Management reiterates ambitious ~$8bn peak sales target for Auvelity, but current revenue trajectory and market dynamics cast doubt on achievability. I downgrade AXSM stock to Sell, citing persistent losses, questionable commercial scalability, and a market cap not justified by near-term revenue or profit outlook. Read the full article on Seeking AlphaAnlatı Güncellemesi • Aug 05
AXSM: Dementia Agitation Approval Will Drive Future Commercial Upside
Axsome Therapeutics' analyst fair value estimate has shifted from $148 to $242, as analysts factor in the recent Auvelity approval in dementia related agitation, higher projected revenue growth, and a richer future P/E assumption, partly offset by lower modeled profit margins and a slightly higher discount rate. Analyst Commentary Recent Street research on Axsome Therapeutics highlights a generally constructive stance on the stock, with a focus on the commercial opportunity for Auvelity and the contribution from other approved products.
Anlatı Güncellemesi • Jul 22
AXSM: Alzheimer’s Agitation Launch Will Drive Future CNS Portfolio Upside
Axsome Therapeutics' analyst fair value estimate has been nudged higher from $276.47 to $282.51, as analysts factor in recent price target increases around $300 to $310 that highlight Auvelity's new Alzheimer's disease agitation indication and potential contributions from products like Sunosi and Symbravo. Analyst Commentary Recent Street research on Axsome Therapeutics has focused heavily on Auvelity's new indication in Alzheimer's disease agitation and the contribution of the broader commercial portfolio, with several firms adjusting price targets into the US$300 to US$310 range.
Anlatı Güncellemesi • Jul 08
AXSM: Alzheimer’s Agitation Approval And ADHD Program Will Reshape Earnings Profile
Axsome Therapeutics’ updated analyst price target has moved from $223.00 to about $348.95, with analysts citing stronger modeled revenue growth, higher profit margins, and a slightly lower future P/E multiple, following a wave of upward target revisions across the Street. Analyst Commentary Recent research on Axsome Therapeutics has been broadly constructive, with multiple bullish analysts revising price targets higher and pointing to specific product and execution drivers that they see as supportive of the company’s valuation.Anlatı Güncellemesi • Jun 24
AXSM: Alzheimer’s Agitation Launch And CNS Pipeline Will Shape Future Outlook
Axsome Therapeutics' analyst fair value target has been raised from $270.28 to $276.47. Analysts point to updated expectations for Auvelity's growth potential, including the recently discussed Alzheimer's disease agitation indication and broader adoption across depression patients, as key drivers behind the shift.Anlatı Güncellemesi • Jun 06
AXSM: Alzheimer’s Agitation Launch Will Drive Future Upside Potential
Analysts have adjusted the Axsome Therapeutics blended price target slightly higher to about $270 per share, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations following a series of mostly upward target revisions across the Street. Analyst Commentary Recent Street research on Axsome Therapeutics has leaned toward higher price targets, with multiple firms adjusting their views following updated assumptions on revenue, profitability, and P/E expectations.Analiz Makalesi • May 07
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$270
Shareholders will be ecstatic, with their stake up 21% over the past week following Axsome Therapeutics, Inc. 's...Anlatı Güncellemesi • May 06
AXSM: Alzheimer’s Agitation Approval Will Drive Future Upside Potential
Axsome Therapeutics' updated analyst price target has shifted higher, with the fair value estimate moving from $223.99 to $266.94 as analysts factor in revised assumptions for revenue growth, profitability, and future P/E, while also acknowledging a slightly higher discount rate. Analyst Commentary Recent Street research on Axsome Therapeutics has been active, with multiple firms revisiting their price targets, fine tuning assumptions around Auvelity, the broader pipeline, and key regulatory milestones such as the AXS-05 PDUFA date for Alzheimer's disease Agitation.Anlatı Güncellemesi • Apr 21
AXSM: Alzheimer’s Agitation Decision Will Drive Future Upside Potential
Axsome Therapeutics’ fair value estimate has ticked up by about $0.33 to $223.99 as analysts factor in higher price targets clustered in the $202 to $251 range, supported by views on Auvelity traction, the potential AXS-05 approval in Alzheimer's disease agitation, and operating leverage. Analyst Commentary Recent research updates on Axsome Therapeutics show a cluster of higher price targets, with several firms adjusting their views following Q4 results, Auvelity trends, and upcoming AXS-05 catalysts.Anlatı Güncellemesi • Apr 07
AXSM: Priority Review In Alzheimer’s Agitation Will Drive Future Upside
Analysts have raised their blended price targets on Axsome Therapeutics by a few dollars, reflecting updated models that incorporate stronger Auvelity traction, the potential AXS-05 Alzheimer's disease agitation opportunity estimated at about $1.6 billion, and revised assumptions about improved operating leverage. Analyst Commentary Recent research updates around Axsome Therapeutics cluster around the same core themes you are likely tracking as an investor, including Auvelity execution, the potential AXS-05 Alzheimer's disease agitation opportunity, and the company's operating leverage and cash generation profile.Anlatı Güncellemesi • Mar 23
AXSM: Priority Review In Alzheimer’s Agitation Will Drive Future Upside
Analysts have raised their blended price targets on Axsome Therapeutics to a range of $202 to $251, citing ongoing Auvelity traction, expectations around the AXS-05 Alzheimer's disease agitation filing, and operating leverage across the broader pipeline as key factors supporting their updated views. Analyst Commentary Street research on Axsome Therapeutics has recently centered on product execution for Auvelity, the potential of AXS-05 in Alzheimer’s disease agitation, and the company’s ability to scale operations efficiently.Anlatı Güncellemesi • Mar 08
AXSM: Priority Review In Alzheimer’s Agitation Will Drive Future Upside
Analysts have lifted their average price target on Axsome Therapeutics by about $6 to roughly $222, citing continued Auvelity traction, expectations around AXS-05 in Alzheimer's disease agitation, and operating leverage supported by an expanding neuroscience pipeline. Analyst Commentary Recent Street research on Axsome Therapeutics points to a generally constructive view, with a series of price target increases clustered around the low to mid US$200s and a mix of Outperform, Buy, Equal Weight, and Overweight ratings.Anlatı Güncellemesi • Feb 21
AXSM: Priority Reviews And Late-Stage CNS Pipeline Will Drive Future Upside
Analysts have inched their fair value estimate for Axsome Therapeutics higher by about $0.65 to roughly $216 per share, reflecting a series of recent price target increases across the Street that cite stronger modeled profitability and updated assumptions around key assets and pipeline progress. Analyst Commentary Recent research on Axsome Therapeutics has been skewed toward higher valuation work, with several firms lifting their price targets and reaffirming positive ratings.Anlatı Güncellemesi • Feb 06
AXSM: Priority Reviews And Late-Stage CNS Portfolio Will Drive Upside
Axsome Therapeutics' updated analyst price target edges higher by about US$5 per share, with analysts pointing to refreshed models that factor in slightly stronger revenue growth expectations, modestly higher assumed valuation multiples, and recent positive readthrough from Auvelity and Sunosi sales and regulatory progress. Analyst Commentary Recent Street research on Axsome Therapeutics centers on updated models following preliminary Q4 results, Auvelity and Sunosi performance, and regulatory milestones tied to priority review decisions.Anlatı Güncellemesi • Jan 23
AXSM: Late-Stage CNS Franchise And Alzheimer’s Agitation Decision Will Drive Upside
Analysts have lifted their blended price target on Axsome Therapeutics by about $14, reflecting updated models that factor in recent Q4 revenue outperformance for Auvelity and Sunosi, an increased assumed revenue growth rate to 51.70%, and a higher future P/E of 20.59x. Analyst Commentary Recent Street research on Axsome Therapeutics has been active, with several bullish analysts lifting price targets following Q3 and preliminary Q4 updates for Auvelity and Sunosi, while one bearish analyst trimmed expectations.Anlatı Güncellemesi • Jan 08
AXSM: Late-Stage CNS Franchise And AXS-05 Readout Will Drive Upside
Narrative Update: Axsome Therapeutics Analysts have lifted their average price target for Axsome Therapeutics by about $15 per share, citing recent model updates that reflect slightly higher revenue growth assumptions, a modestly richer future P/E multiple, and Street research pointing to steady commercial progress for Auvelity, Symbravo and Sunosi, along with potential upside from the AXS-05 program. Analyst Commentary Bullish analysts are generally constructive on Axsome Therapeutics, pointing to product execution, model updates and potential pipeline upside as reasons for lifting their valuation work.Anlatı Güncellemesi • Dec 24
AXSM: Late-Stage CNS Pipeline Will Drive Future Upside Potential
Axsome Therapeutics' analyst price target edges higher by approximately $5 to the mid-$190s as analysts point to stronger long term revenue growth, expanding profit margin expectations, and resilient demand for key commercial assets as justification for the upward revision. Analyst Commentary Recent Street research on Axsome Therapeutics reflects a predominantly constructive stance, with multiple price target increases into the mid to high $180s.Analiz Makalesi • Nov 07
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Investors in Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) had a good week, as its shares rose 3.3% to close at US$139...Anlatı Güncellemesi • Nov 07
AXSM: Commercial Execution And Late-Stage Pipeline Will Drive Strong Upside Potential
Axsome Therapeutics' fair value estimate has been raised by analysts from $176.84 to $181.58. This change reflects upward price target revisions, as analysts express optimism about the company's progress toward profitability and effective commercial execution following recent quarterly results.
Yeni Anlatı • Apr 28
R&D Pipeline And NDAs Will Unlock New Approvals
Ongoing R&D and product launch efforts, including key NDA submissions, may significantly enhance future revenues through new product approvals.Seeking Alpha • Feb 20
Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering
Summary Axsome Therapeutics' stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth, but I maintain a "sell" rating. Despite Auvelity's revenue growth, significant SG&A and R&D expenses persist, and Symbravo's market potential in the crowded migraine space remains uncertain. Axsome's pipeline includes high-risk CNS indications with historically high attrition rates, and recent trial results have been mixed, questioning future success. Financially, Axsome has solid liquidity with a cash runway into mid-2027, but sustained cash burn and lack of clear revenue breakaway warrant cautious investment. Read the full article on Seeking AlphaSeeking Alpha • Feb 11
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Summary Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity and Sunosi are crucial, with Auvelity expected to generate over 75% of 2025 revenues; as such, today's news is a significant win. Despite high competition in MDD and other markets, Axsome's pipeline, including AXS-07 and AXS-12, shows potential for substantial revenue growth. I now rate AXSM stock a “Buy,” anticipating ~$2.5bn peak revenues long-term, and potentially a double-digit billion market cap, given upcoming data catalysts and multiple “shots on goal." Read the full article on Seeking AlphaSeeking Alpha • Dec 31
Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results
Summary Axsome Therapeutics shows strong revenue growth from Auvelity and Sunosi, with promising late-stage pipeline drugs for migraine, fibromyalgia, and narcolepsy. Late-stage pipeline milestones include AXS-07 for migraine (PDUFA: January 31, 2025), AXS-12 for narcolepsy, and AXS-14 for fibromyalgia. Despite mixed Phase 3 results for AXS-05 in Alzheimer's agitation, the overall data is favorable, supporting a bullish outlook. AXSM stock's valuation appears high, but its revenue potential and cash runway suggest it could become cash flow positive by 2025. Regulatory risks and premium valuation are concerns, but Axsome's diverse portfolio and successful IPs mitigate investment risks, making it a “Buy”. Read the full article on Seeking AlphaSeeking Alpha • Nov 29
Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data
Summary Axsome's AXS-12 met its primary endpoint in a Phase 3 study, significantly reducing cataplexy attacks in narcolepsy patients, positioning it for an NDA submission. The narcolepsy market is substantial, with current treatments having issues like tolerability and efficacy, which AXS-12 aims to address effectively. Financially, Axsome has a market cap of $4.83bn, strong revenue growth, but a net loss, indicating a cash runway of four to five quarters. Axsome is in a catalyst-heavy period with multiple NDA submissions and upcoming trial results, making it a strong buy before the January PDUFA. Read the full article on Seeking AlphaSeeking Alpha • Nov 12
Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell
Summary Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m, up 81% YoY, but net loss increased to $(64.6m). Despite positive market response and promising pipeline candidates, Axsome's profitability remains distant, with significant cash burn and competition from pharma giants. AXS-07 is likely to gain FDA approval in January for migraine treatment, while AXS-05 shows potential for Alzheimer's agitation, but “blockbuster” revenue status is uncertain. Management says it sees multi-billion dollar revenue potential in Solriamfetol, a drug acquired for $53m from Jazz Pharma — I don't agree. Given the high volatility and upcoming data readouts, holding AXSM stock may be wise, but selling on any price spike is recommended. Read the full article on Seeking AlphaSeeking Alpha • Oct 15
Axsome: AXS-07 And Its Upcoming Second PDUFA
Summary AXS-07, targeting chronic migraine, has shown promising results in Phase 3 trials but faced a CRL from the FDA due to CMC issues. The FDA has set a new PDUFA date for AXS-07 on January 31, 2025, potentially leading to a significant stock boost upon approval. Axsome's financials show a market cap of $4.1bn and a cash runway of 4-5 quarters, but risks include potential dilution and FDA approval uncertainty. Despite concerns, AXSM remains a strong biotech investment, with plans to hold and buy on dips, anticipating AXS-07's market potential. Read the full article on Seeking AlphaSeeking Alpha • Aug 06
Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
Summary Axsome Therapeutics reported Q2 2024 revenues of $87.2 million, with Auvelity sales growing 135% year-over-year. The company’s SG&A and R&D expenses significantly increased, leading to wider net losses despite revenue growth. Auvelity faces stiff competition in the depression market, with uncertain positioning and high marketing expenses. Given Axsome’s financial risks and high operational costs, I recommend a "sell" rating on AXSM stock. Read the full article on Seeking AlphaSeeking Alpha • Jul 23
Axsome Therapeutics: Lots Of Moving Parts
Summary Today, we circle back to mid-cap biopharma Axsome Therapeutics, which has multiple potential catalysts on the horizon. The company has two approved products on the market and the potential to have six FDA approved drugs by the end of 2025. Analyst firms are largely positive on the shares, and explosive sales growth is projected over the next few years. An updated analysis around Axsome Therapeutics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • May 10
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
Summary Axsome Therapeutics develops treatments for CNS conditions, with two commercial products: Auvelity for major depressive disorders and Sunosi for sleep disorders. The company has a diverse pipeline targeting illnesses such as Alzheimer's disease, smoking cessation, migraine, narcolepsy, and more. Axsome's portfolio addresses the medical needs of over 150 million people and has the potential to generate peak sales of up to $16.5 billion. Axsome maintains a strong cash position and manageable debt. Significant revenue growth is projected, supporting its intense research efforts. I rate AXSM a “buy” due to its high potential in a large market and promising financial outlook despite inherent biotech risks. Read the full article on Seeking AlphaHissedar Getirileri
| AXSM | US Pharmaceuticals | US Pazar | |
|---|---|---|---|
| 7D | 0.4% | 0.6% | 0.6% |
| 1Y | 95.6% | 49.9% | 20.1% |
Getiri vs. Endüstri: AXSM geçen yıl % 49.9 oranında getiri sağlayan US Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: AXSM geçen yıl % 20.1 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| AXSM volatility | |
|---|---|
| AXSM Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 9.0% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: AXSM son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: AXSM 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2012 | 1,346 | Herriot Tabuteau | www.axsome.com |
Bir biyofarmasötik şirketi olan Axsome Therapeutics, Inc. ABD'de merkezi sinir sistemi (MSS) bozukluklarının yönetimi için yeni tedaviler geliştirmekte ve sunmaktadır. Şirketin ticari ürün portföyü, yetişkinlerde majör depresif bozukluğun tedavisi için endike bir N-metil-D-aspartat reseptör antagonisti, sigma-1 reseptör agonisti, aminoketon ve CYP2D6 inhibitörü olan Auvelity'yi (dekstrometorfan-bupropion) içerir; Sunosi (solriamfetol), narkolepsi veya obstrüktif uyku apnesi olan hastalarda gündüz aşırı uyku halinin tedavisinde endike bir dopamin ve norepinefrin geri alım inhibitörü, eser amin ilişkili reseptör 1 agonisti ve 5-HT1A agonisti; ve Symbravo (MoSEIC meloksikam rizatriptan) veya AXS-07, auralı veya aurasız migrenin akut tedavisinde endike, hızla emilen, çok mekanizmalı, seçici bir COX-2 inhibitörü ve 5-HT1B/1D agonistidir. Ayrıca, Alzheimer hastalığı ajitasyonunu tedavi etmek için Faz III klinik çalışmasını tamamlayan ve sigarayı bırakma tedavisi için Faz II klinik çalışmasını tamamlayan araştırma amaçlı bir N-metil-D-aspartat reseptör antagonisti olan AXS-05'i (dekstrometorfan-bupropion); narkolepsi tedavisi için Faz II çalışmasını tamamlayan oldukça seçici ve güçlü bir norepinefrin geri alım inhibitörü ve kortikal dopamin modülatörü olan AXS-12'yi (reboxetine) geliştirmektedir; AXS-14 (esreboxetine), fibromiyalji ve diğer durumların tedavisi için Faz III denemesini tamamlamış seçici ve güçlü bir norepinefrin geri alım inhibitörü; ve Solriamfetol, bir dopamin ve norepinefrin geri alım inhibitörü, dikkat eksikliği hiperaktivite, majör depresif, aşırı yeme ve vardiyalı çalışma bozukluğu ile ilişkili aşırı uykululuk tedavisi için Faz III denemesinde.
Axsome Therapeutics, Inc. Temel Bilgiler Özeti
| AXSM temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$11.19b |
| Kazançlar(TTM) | -US$191.64m |
| Gelir(TTM) | US$776.57m |
14.4x
P/S Oranı-58.4x
F/K OranıAXSM aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| AXSM gelir tablosu (TTM) | |
|---|---|
| Gelir | US$776.57m |
| Gelir Maliyeti | US$52.53m |
| Brüt Kâr | US$724.04m |
| Diğer Giderler | US$915.68m |
| Kazançlar | -US$191.64m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -3.66 |
| Brüt Marj | 93.24% |
| Net Kâr Marjı | -24.68% |
| Borç/Özkaynak Oranı | 225.6% |
AXSM uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/16 12:57 |
| Gün Sonu Hisse Fiyatı | 2026/08/14 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Axsome Therapeutics, Inc. 37 Bu analistlerden 20, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Joel Beatty | Baird |
| Brian Skorney | Baird |
| null null | Baird |